Publications
Discover peer-reviewed publications by therapeutic area.
The information on this page pertains to select publication resources. It is not intended to serve as a comprehensive list of all publications resources.
If you would like to discover more educational content, please use the “Search” feature.
Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
The provision of this content is not intended to recommend or suggest use of its products in any manner inconsistent with local regulatory approval. For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Transthyretin Amyloidosis (ATTR)
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial
European Journal of Heart Failure
Transthyretin Amyloidosis (ATTR)
Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis
Clinical Pharmacokinetics
Transthyretin Amyloidosis (ATTR)
Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B
JACC: Asia
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B
Journal of Cardiac Failure
Transthyretin Amyloidosis (ATTR)
Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE
Clinical Medicine Insights: Cardiology
Transthyretin Amyloidosis (ATTR)
Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study
European Journal of Heart Failure
Transthyretin Amyloidosis (ATTR)
Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A
Neurology and Therapy
Primary Hyperoxaluria Type 1 (PH1)
Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1
Clinical Journal of the American Society of Nephrology
Transthyretin Amyloidosis (ATTR)
Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial
European Journal of Heart Failure
